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Abstract
Post-translational modifications significantly broaden the epitope repertoire for major histo-
compatibility class I complexes (MHC-I) andmay allow viruses to escape immune recognition.
Lymphocytic choriomeningitis virus (LCMV) infection of H-2b mice generates CD8+ CTL
responses directed towards several MHC-I-restricted epitopes including the peptides GP92
(CSANNSHHYI) andGP392 (WLVTNGSYL), both with a N-glycosylation site. Interestingly,
glycosylation has different effects on the immunogenicity and association capacity of these
two epitopes to H-2Db. To assess the structural bases underlying these functional results, we
determined the crystal structures of H-2Db in complex with GP92 (CSANNSHHYI) andGP392
(WLVTNGSYL) to 2.4 and 2.5 Å resolution, respectively. The structures reveal that while gly-
cosylation of GP392most probably impairs binding, the glycosylation of the asparagine resi-
due in GP92, which protrudes towards the solvent, possibly allows for immune escape and/or
forms a neo-epitope that may select for a different set of CD8 T cells. Altogether, the pre-
sented results provide a structural platform underlying the effects of post-translational modifi-
cations on epitope binding and/or immunogenicity, resulting in viral immune escape.
Introduction
The impact of post-translational modifications (PTMs) on disease progression is now well
established [1–3]. PTMs such as deamidation [4], cysteinylation [5], nitrotyrosination [6,7],
glycosylation [8,9] or phosphorylation [10,11] alter the epitope repertoire in a large ensemble
of diseases including cancers [12–14], autoimmune disorders [15,16] and viral infections
[17,18]. PTMs may result in the generation of disease-specific immunogenic neo-epitopes [19]
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and/or allow for immune escape [20]. Glycosylation is one of the most common PTMs, with
important consequences for MHC-I and MHC-II presentation, and consequently T cell recog-
nition [21–24]. There are commonly three types of constitutive glycans [19,22,25]. While N-
linked glycans use a N-acetylglucosamine (GlcNAc) sugar moiety that binds to the side chain
of the asparagine residue within the conserved motif Asn-X-Ser/Thr where X 6¼ Pro, O-linked
glycans bind to serine or threonine residues via a sugar moiety such as GlcNAc without any
consensus sequence pre-requirement. The third type of glycosylation includes the carbohy-
drate components of glycosylphosphatidylinositol (GPI) anchors. T cell responses against O-
glycosylated proteins can be significantly influenced by the nature and the position of peptide-
attached sugar moieties [9,19,22,26]. N-linked glycosylation can also give rise to secondary de-
glycosylation, resulting from the conversion of asparagine to aspartate [27], which ultimately
means that a potentially N-linked glycosylation site can exist in three different forms, wild-
type (WT), glycosylated (GlcNAc) and deglycosylated (D).
The addition of N-linked glycans to nascent polypeptides occurs co-translationally in the
endoplasmic reticulum (ER), as part of their maturation [28]. The glycosylation state serves as
an indicator for a large amount of proteins, allowing the ER quality control system to monitor
the conformation and the appropriate fold of these polypeptides. Proteins that are inade-
quately folded are often dislocated to the cytoplasm, where they are subjected to proteasomal
degradation. Specific recognition and elimination of tumors and/or pathogen-infected cells by
cytolytic CD8+ T lymphocytes (CTLs) critically relies on the presentation of antigenic peptides
by MHC class I molecules (MHC-I) at the cell surface. The antigenic peptide repertoire is gen-
erated from mature and immature proteins (defective ribosomal products, DRiPs), which
depends mainly on degradation by the proteasome during or after their synthesis [29,30].
Since many antigens are glycoproteins, including tumor-associated and pathogen-derived
molecules, the glycosylation status of these epitopes may affect their processing and the
amount that is presented on the cell surface [31].
Although the de-facto MHC-I presentation of N-glycosylated peptides on the surface of
healthy, stressed or infected cells has still not be proven, studies have demonstrated that
MHC-I-restricted N-glycosylated epitopes can elicit highly efficient CD8 T cell responses [23].
Furthermore, a fundamental previous study has provided direct evidence that the proteasome
is fully capable of degrading glycoproteins without prior removal of their glycans [32]. While
the addition of N-linked glycans always occurs within the ER, potential removal of the glycans
takes place in the cytosol through the action of the peptide N-glycanase (PNGase). The same
study also demonstrated that the presence of a glycan near an MHC-I-restricted epitope mod-
ulates its presentation [32].
Others and we have previously addressed from a structural point of view how specific viral
escape mutations and/or PTM in MHC-I-restricted epitopes alter significantly T and NK-cell
recognition [6,9,26,33–35]. In particular, the effects of glycosylation and nitrotyrosination on
the formation of neo-epitopes that select for PTM-specific T cells were described [6,26]. Often,
the same PTM in the same epitope reduced significantly binding capacity when restricted to
one MHC allele, while forming a neo-epitope when binding to another MHC allele, allowing
for both immune escape and selection of a novel CTL repertoire [6,9,26,34,35]. Furthermore,
clear possibilities for TCR cross-reactivity were also suggested by at least one study [9].
The LCMV (Lymphocytic Choriomeningitis Virus)-derived epitopes GP92 (CSANNSH-
HYI) and GP392 (WLVTNGSYL) were initially identified and characterized by using peptide
libraries based on the H-2Db binding motif within LCMV protein sequences [36]. The se-
quences corresponding to these two epitopes are naturally glycosylated in the full length
protein version [23,24,37]. More recently, the crystal structure of the prefusion surface glyco-
protein, from which both these peptides are derived, demonstrated clearly that the asparagine
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residues at position 4 and 5 of GP92 and GP392, respectively, are both glycosylated [38] (S1
Fig). Thus, both epitopes carry the N-linked glycosylation pattern, with well-established func-
tional effects [23,24]. However, the introduced glycosylation modifications have opposite
effects on GP92 and GP392 epitopes. Indeed, the sub-dominant peptide GP92 and its modified
forms GlcNAc-GP92 and D-GP92 are all immunogenic [23]. Vaccination with any of these
three variants triggers efficient T cell activation in mice models but only CTLs generated with
either wild-type GP92 or D-GP92 can kill LCMV-infected cells [23,24]. However, T cells raised
against the GlcNAc-GP92 epitope cannot lyse LCMV-infected cells, indicating that this epi-
tope is not naturally presented or that the amounts presented on the cell surface are very lim-
ited [23]. In contrast to GP92, GP392 is immunogenic only in its genetically-encoded form
when used for vaccination in mice; T cells could not be raised towards neither GlcNAc-GP392
nor the de-glycosylated variant D-GP392 [24]. Interestingly, the binding affinity of the two
modified versions of GP392 were significantly reduced compared to the unmodified GP392
[24]. Most importantly, neither unmodified GP392 nor the PTM GP392 epitope variants were
detected on the cell surface of LCMV-infected cells, reducing the potential for using any of
these epitopes for vaccination attempts [24].
The main aims of the present study were to determine the crystal structures of H-2Db in
complex with the LCMV-derived epitopes GP92 and GP392 and possibly unveil the structural
mechanisms underlying the differential immunogenicity of these two epitopes and their
respective glycosylated isoforms. To our knowledge, our results represent the first structural
analysis of the differences introduced by peptide glycosylation on the immunogenicity of
MHC-I-restricted LCMV-associated epitopes. Additionally, the two crystal structures solved
within this study provide further insights on the potential effects of PTMs on viral immune
escape from cytotoxic T Lymphocytes (CTL) responses as well as how PTM can generate
immunogenic neo-epitopes.
Materials andmethods
Production and crystallization of H-2Db in complex with GP92 andGP392
Peptides GP92 (CSANNSHHYI) and GP392 (WLVTNGSYL) were produced by microwave-
assisted solid phase synthesis based on Fmoc chemistry [39] on a CEM Liberty peptide synthe-
sizer. Peptides were purified by RP-HPLC on a Jasco BS-997-01 instrument equipped with a
DENALI C-18 column from GRACE VYDAC (10μm, 250 x 22mm). The refolding and purifi-
cation of H-2Db in complex with GP92 or GP392, and mouse β2-microglobulin (β2m) were
conducted as described earlier [6,34,40–43]. Ion-exchange chromatography was used as an
additional purification step, using a Mono Q column (GE Healthcare), for both complexes.
The best crystals for the H-2Db/GP92 and H-2Db/GP392 complexes were obtained by hanging
drop vapor diffusion in 100 mM ammonium sulfate, 100 mM Tris-HCl (pH 7.5), 25% PEG
6000 and 1.8 M ammonium sulfate, 100 mM Tris-HCl (pH 8.0), respectively. Typically, 2 μl of
H-2Db/GP92 (2 mg/ml) and 4 μl of H-2Db/GP392 (5 mg/ml), both in 100 mM Tris-HCl, pH
7.5, were mixed at a 2:1 ratio with the crystallization reservoir solution at 4˚C.
Data collection and processing
Crystals were soaked in reservoir solutions complemented with 15% glycerol before flash-
freezing in liquid nitrogen. Data sets for the H-2Db/GP92 and H-2Db/GP392 complexes were
collected at a wavelength of 0.933 Å under cryogenic conditions (temperature 100 K) at the
beamline ID14-1 at the European Synchrotron Radiation Facility (ESRF Grenoble, France) to
2.4Å and 2.5Å resolution, respectively. The data were processed with MOSFLM [44] and
SCALA [45] from the CCP4 suite [46]. While the space group of the H-2Db/ GP92 crystal was
Structural bases underlying opposing effects of glycosylation on immunogenicity andMHC peptide presentation
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determined to be P21 with four molecules in the asymmetric unit, the crystal of H-2D
b/GP392
belongs to the space group C2 with one molecule in the asymmetric unit. Data collection statis-
tics are provided in Table 1.
Structure determination and refinement
The crystal structures of the H-2Db/GP92 and H-2Db/GP392 complexes were solved by molec-
ular replacement using the program PHASER [47] and the crystal structure of H-2Db/gp33
[34] (PDB code 1N5A), with the peptide omitted, as a search model. Clear and continuous
electron densities were observed in the peptide binding clefts in both structures, allowing for
unambiguous modelling of the epitopes CSANNSHHYI and WLVTNGSYL. Five percent of
the reflections were set aside in both cases for use as a test set for cross-validation. Refinements
were carried out using Phenix [48] and manual rebuilding using Coot [49]. The final refined
structures were deposited at the PDB under the accession codes 5JWD and 5JWE for GP392
and GP92, respectively. The final refinement parameters are presented in Table 1. All figures
were generated using Pymol [50].
Table 1. Data collection and refinement statistics.
H-2Db/CSANNSHHYI H-2Db/WLVTNGSYL
Data Collection
Space group P21 C2
Unit-cell parameters (Å, Ê) a = 85.5, b = 176.3, c = 85.6 a = 90.3, b = 108.8, c = 58.0
α = γ = 90, β = 119.8 α = γ = 90, β = 121.9
Resolution 19.61±2.4 (2.43±2.4) 19.76±2.5 (2.66±2.5)
1Rmerge 7.0 (69.0) 10.0 (40.3)
I/σ(I) 12.7 (1.8) 12.2 (3.4)
Completeness (%) 94.2 (91.0) 99.5 (99.2)
Multiplicity 3.6 (3.6) 3.6 (3.6)
Refinement
No. of reflection 84550 (2598) 16374 (2590)
2Rwork 0.1994 (0.3476) 0.1801 (0.2523)
3Rfree 0.2589 (0.3997) 0.2291 (0.2857)
R.m.s.d
Bond lengths (Å) 0.010 0.010
Bond angles (Ê) 1.241 1.202
Ramachandran outliers 0 0
Ramachandran favored 97.81% 0,97
Mean B factor (Å2) 67.87 58.0
Values in parentheses are for the highest resolution shell.
1 Rmerge = ∑hkl ∑i │Ii (hkl)Ð ‹I (hkl)›│/∑hkl ∑i Ii (hkl), where Ii(hkl) is the ith observation of reflection hkl and ‹I (hkl)› is the weighted average intensity for all
observations i of reflection hkl.
2 Rwork = Σ||Fo|Ð|Fc|| /Σ|Fo|, where |Fo| and |Fc| are the observed and calculated structure factor amplitudes of a particular reflection and the summation is
over 95% of the reflections in the specified resolution range. The remaining 5% of the reflections were randomly selected (test set) before the structure
refinement and not included in the structure refinement.
3 Rfree was calculated over these reflections using the same equation as for Rcryst.
https://doi.org/10.1371/journal.pone.0189584.t001
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Results
The 3D structures of H-2Db/GP92 and H-2Db/GP392 are prototypic for
MHC-I/peptide complexes
The crystal structures of H-2Db in complex with the LCMV-derived peptides GP92 (CSANN
SHHYI) and GP392 (WLVTNGSYL) were refined to 2.4 and 2.5 Å resolution, respectively
(Table 1). Rfree/Rcryst for the final models of GP92 and GP392 were 25.9/19.9% and 23.5/21.6%,
respectively, which is typical for structures at these resolutions. The overall structures of the
complexes are very similar to each other and display the classical configuration for MHC-I/
peptide complexes (Fig 1A and 1B) with both epitopes bound within the peptide binding cleft
[51]. The peptide-binding domains of these two MHC-I/peptide complexes are highly similar
to each other with an overall root mean square deviation (rmsd) value of 0.78Å for 170 Cα
atoms (residues 3–173) in the α1 and α2 domains of the heavy chain. Moreover, their three-
dimensional structures are very similar to previously determined crystal structures of H-2Db
in complex with e.g. the immunodominant LCMV-derived peptide gp33 [35], with an rmsd
value of 0.66Å for H-2Db/GP92 and 0.87Å for H-2Db/GP392, respectively. The stereochemis-
try of both crystal structures is as expected for models at these resolutions (Table 1). The
bound peptides and all residues forming the binding cleft of H-2Db are clearly defined in
unambiguous 2Fo-Fc electron density maps (Fig 1C and 1D).
The LCMV-derived epitopesGP92 and GP392 bind conventionally to
H-2Db
The peptide-binding groove of H-2Db is closed at both ends restricting most bound peptides to
8–10 residues. In both complexes, the fifth peptide residue (asparagine p5N) and the C-terminal
residue act as anchor positions, binding to the C- and F-pockets in H-2Db, respectively [52].
Indeed, the decamer GP92 employs p5N and p10I as main anchor residues for binding to H-2Db.
A small section of the C-terminal part of GP92, composed of residues p6S-p9Y, bulges out from
the groove in order to accommodate the anchor residue p10I within the F-pocket (Figs 1C and
2A) [53]. The other main anchor residue p5N forms two hydrogen bonds with the H-2Db residue
Q97, and an additional hydrogen bond with the H-2Db residue Q70 (Fig 3A). The side chain of
residue p10I fits well within the hydrophobic F-pocket of H-2Db composed by residues W73, L81,
L95, F116, I124 and W147 (Fig 3B). Its main chain atoms also form an intricate network of hydro-
gen bonds with the H-2Db residues S77, N80, Y84, T143 and K146 (Fig 3B). All other peptide resi-
dues, except the bulging histidine residue p7H and non-anchoring residue p3A, form hydrogen
bonds between their backbone atoms and the side chains of H-2Db residues (S2 Fig).
The nonameric GP392 binds to the peptide binding cleft in a classical elongated conformation
(Figs 1D and 2B). Similarly to GP92, GP392 utilizes residues p5N and p9L as main anchor resi-
dues (Fig 3C and 3D). Residues p5N and p9L use approximately the same hydrogen bond pattern
as GP92, besides two hydrogen bonds that are missing due to a shift in the main chain oxygen of
residue p4N causing the distance to H155 and Y156 to increase. It should be noted that the leucine
residue p9L is considered as a weaker anchor in the F-pocket, compared to strong anchors such
as isoleucine or methionine, with a following reduction in hydrophobic interactions [53].
The glycan-binding asparagine residue is exposed in GP92 and buried in
GP392
In GP92, residue p4N that can be glycosylated protrudes towards the solvent and is fully acces-
sible to T cell receptors (TCRs) (Fig 4A). Thus, in line with the observations of Hudrisier et al
[24], modifications targeting this residue should not significantly affect the binding capacity of
Structural bases underlying opposing effects of glycosylation on immunogenicity andMHC peptide presentation
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Fig 1. H-2Db/GP92 and H-2Db/GP392 have highly similar overall fold. Cartoon representations of the extracellular domains of the H-2Db/
GP92 complex (A) with the peptide in orange and the H-2Db/GP392 complex (B) with peptide in blue demonstrate classical MHC-I overall
structures, with the peptides bound between the helices of the α1 and α2 domains. (C and D) 2FoFc electron density map contoured at 1σ level
defines unambiguously the conformation of the peptides. Peptides are shown in stick representation with N-terminus to the left. (C) The
Structural bases underlying opposing effects of glycosylation on immunogenicity andMHC peptide presentation
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the altered peptide(s) to H-2Db. As previously mentioned, vaccination with wild-type or any
of the two PTM GP92 variants generated T cells selectively cytotoxic to LCMV-infected cells
[23]. Based on the crystal structure of H-2Db/GP92 solved in this study, we created molecular
models of the different PTM versions of GP92 known to bind to H-2Db (Fig 4B and 4C), indi-
cating that both the glycan moiety at p4 and the modified residue p4D protrude from the cleft,
and explaining the functionally observed efficient T cell triggering for all three GP92 peptide
variants [23]. Indeed, as T cells activated by GlcNAc-GP92 or D-GP92 cannot efficiently cross-
react with the wild-type epitope [23], both the wild-type epitope and each PTM version are
most probably recognized by different TCR populations.
In contrast to GP92, the crystal structure of H-2Db/GP392 indicates that the asparagine res-
idue p5N that can be glycosylated is essential for peptide binding to H-2Db (Figs 1D, 3C and
decameric GP92 takes a bulged conformation when binding to the H-2Db cleft. Residues p7H and p8H project towards the solvent and, together
with p4N and p9Y, protrude towards the TCR. The side chains of residues p5N and p10I anchor the peptide to H-2Db. (D) The epitopeGP392
takes an elongated conformation with residues p5N and p9L anchoring to the peptide binding cleft and residues p4T and p8Y directed towards
the TCR.
https://doi.org/10.1371/journal.pone.0189584.g001
Fig 2. The peptides GP92 and GP392 bound to the cleft of the H-2Db molecule. Peptides are presented as
sticks and the H-2Db molecule is shown as a surface colored according to the electrostatic potential with red and
blue corresponding to negative and positive charges, respectively. The C- and F-pockets, docking sites for the
anchor residue p5N and the C-terminal residue, respectively, are indicated.
https://doi.org/10.1371/journal.pone.0189584.g002
Structural bases underlying opposing effects of glycosylation on immunogenicity andMHC peptide presentation
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5A). Addition of the sugar not only disrupts the fork-like hydrogen bonds formed between
p5N and the H-2Db residue Q97, but also transforms the glycosylated p5N position into a
much larger residue unsuitable for binding into pocket C (Figs 3C and 5B). However, previous
studies have also demonstrated that the glycosylated version of GP392 still can bind to H-2Db,
although with much weaker affinity compared to the wild-type GP392 [24]. Furthermore,
other crystal structure studies of glycosylated peptides in complex with H-2Db have demon-
strated that a glycan at peptide position 5 such as in the epitope K2G protrudes out of the cleft
instead of pointing towards the H-2Db residue Gln97 [9]. Consequently, the K2G peptide
takes a profoundly different conformation in its middle part while both the N- and C-termini
of the peptide take very similar conformations compared to the wild-type peptide. Here
instead, the tyrosine residue at peptide position 6 in K2G acts as a novel anchor position, re-
sulting in efficient binding to H-2Db [9]. Therefore, we also created a molecular model of H-
2Db with GlcNAc-GP392 that indicates that the glycosylated residue at position 5 can also
point out of the cleft (Fig 5C). However, the glycine residue at position 6 cannot act as an
anchoring position substitute as in the complex of H-2Db with K2G, providing a possible
explanation to its much weaker affinity to H-2Db, compared to GP392.
It is well-established that any variation in anchor residues may alter considerably the capac-
ity of modified peptides to bind to MHC-I [54]. The molecular model of the deglycosylated
peptide variant D-GP392 demonstrates this clearly (Figs 3C and 5D), since the single atom dif-
ference between aspartate and asparagine, abrogates interactions with Q97 and results in a sig-
nificant reduction in peptide affinity to H-2Db [24]. Analysis of the crystal structure also
Fig 3. The twomain anchor residues are using hydrogen bonds and hydrophobic interactions for
binding to H-2Db. H-2Db residues shown in grey interact with anchor residues of GP92 (cyan) (A-B) and
GP392 (magenta) (C-D). The conformation and the interaction of residue p5N in GP92 (A) andGP392 (C) are
almost identical. Residue E9 is responsible for the slightly negative charge of the pocket C, impairing docking
of e.g. aspartate residues in the C-pocket. The heavy chain oxygen of peptide residue p5N in GP92 is directed
towards the H-2Db residues H155 and Y156, forming hydrogens bonds. In contrast, the oxygen residue in
GP392 does not form any interaction with H155 nor Y156. The details of the interactions of the GP92 and
GP392 C-terminal residues p10I and p9L within the F-pocket are presented in (B) and (D), respectively.
Though isoleucine and leucine residues are rather similar in size and hydrophobicity, the shape of the F
pocket fits better for isoleucine residue p10I (B) rather than leucine (D).
https://doi.org/10.1371/journal.pone.0189584.g003
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reveals the presence on the bottom of the peptide-binding cleft of the negatively charged resi-
due D9 (Fig 3C), which renders pocket C (also formed by residues Q70 and Q97) more acidic.
Thus, pocket C is a perfect docking site for polar uncharged asparagine residues whereas
Fig 4. Molecular models of glycosylated and de-glycosylated GP92 indicate the possible formation of
neo-antigens following PTM. (A) The crystal structure of the H-2Db/GP92 complex indicates that residues
p4N and p7H are likely important for interactionswith TCRs. (B) Potential glycosylation of p4N in GlcNAc-
GP92 would result in the creation of a neo-antigen. (C) Deamidation of p4N in D-GP92 would also result in the
formation of a neo-epitope potentially recognized by a different TCR population compared to the wild-type
epitope.
https://doi.org/10.1371/journal.pone.0189584.g004
Structural bases underlying opposing effects of glycosylation on immunogenicity andMHC peptide presentation
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Fig 5. Molecular models of glycosylated and de-glycosylated GP392 explain reduced binding to H-
2Db as well as possibilities for the formation of neo-epitopes. (A) The main anchor residue p5N in the
Structural bases underlying opposing effects of glycosylation on immunogenicity andMHC peptide presentation
PLOSONE | https://doi.org/10.1371/journal.pone.0189584 December 18, 2017 10 / 17
modification to a negatively charged aspartate is unfavorable. Overall, our results demonstrate
that glycosylation may both reduce significantly binding affinity and thus presentation capac-
ity and/or alter the conformation of the presented epitopes, possibly allowing for immune
escape and/or forming a neo-epitope that may select for a different set of CD8 T cells.
Discussion
Post-translational modifications affect the characteristics of diseases including e.g. cancers
[12–14], autoimmune disorders [15,16] and viral infections [17,18]. Even though these studies
have demonstrated their clear impact on these diseases, the contrasting effects of PTMs on
immunogenicity and binding affinity require further investigations in order to progress epi-
tope vaccination design. Indeed, glycosylation, one of the most common PTMs, has significant
impact on MHC-I epitope repertoire and immunogenicity [13]. We based the present struc-
tural analysis on the LCMV-derived H-2Db-restricted epitopes GP92 and GP392 which both
comprise the classical motif for glycosylation. However due to the different location of these
sites on GP92 and GP392, glycosylation results in diametrically different effects on peptide
binding and immunogenicity in these two different peptide models [24].
GP92 and GP392 share p5N as a primary anchoring residue, important for binding to H-
2Db due to its polarity and the formation of a hydrogen bond network with H-2Db residues
inside the C pocket (Fig 3A and 3C). The majority of the deposited crystal structures and pep-
tides eluted from H-2Db+ cells comprise an asparagine at position 5 in the peptides as pre-
ferred anchor residue for C pocket [53] with exceptions such as the recently identified cancer-
associated TEIPP neo-epitope Trh4, that is presented exclusively on antigen processing defi-
cient cells [55–57], and a mutated version of the influenza A epitope NP366 [58]. Accordingly,
any PTM introduced at position 5 in GP392 will have significant consequences for its binding
ability to H-2Db. Thus if pointing down towards the peptide-binding cleft, this sugar moiety
should prevent/reduce peptide binding (Fig 5B), explaining the significant reduction in bind-
ing and immunogenicity in vaccination trials [24]. On the other hand, as previously demon-
strated [9], PTM at peptide position 5 can result in profound conformational modifications
within the middle part of H-2Db-restricted epitopes, resulting in the presentation of the glycan
towards TCR and away from the peptide-binding cleft. Indeed, molecular modeling of H-2Db
in complex with GlcNAc-GP392 indicates also the possibility for the glycan moiety to be pre-
sented at the TCR interface through a significant conformational modification in the central
part of the epitope (Fig 5C). In contrast to previous studies, the glycine residue at position 6 of
GP392 cannot compensate for the lost interactions with the H-2Db residue Gln97. In conclu-
sion, this alternative conformation could result in the creation of a neo-antigen. Furthermore,
it could also explain the reduced binding ability of the glycosylated peptide. The altered pep-
tide variant D-GP392 (Fig 5D) differs from GP392 in only one atom, the oxygen OD1 instead
of the nitrogen ND1. Nonetheless, D-GP392 binds to H-2Db with a significantly reduced affin-
ity of 2–3 order magnitude compared to the wild-type epitope [24].
Though the unmodified GP392 is a promising candidate for binding and presentation [53],
it has hitherto not been detected on the surface of LCMV-infected cells [24]. It is now well
unmodified GP392 forms hydrogen bondswith residueQ97 localized in the bottom of the peptide binding cleft
of H-2Db. (B) Molecularmodeling indicates that the introduction of the smallest possible sugar moiety GlcNAc
induces sterical clashes that impairs binding. (C) Molecularmodeling also indicates that glycosylation of p5N
could result in profound conformational modifications within themiddle part of the epitope, that could allow
presentation of the glycanmoiety towards the TCR. (D) The negatively charged p5D residue in the de-
glycosylated D-GP92 is directly unfavorable for binding to the C-pocket, due to incompatibilities with the H-
2Db residues E9 andQ97.
https://doi.org/10.1371/journal.pone.0189584.g005
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established that this epitope is glycosylated in the native protein [24,38]. It should be noted
that the consensus sequence Asn-X-Ser/Thr is not the only parameter for an effective N-glyco-
sylation; it has indeed also been shown that the N-linked glycan occupancy is dependent on
the conformation of the glycosylated part of the protein [59]. Several possibilities may explain
the fact that presence of glycosylated GP392 on the cell surface has hitherto not been demon-
strated. One possibility is that GlcNAc-GP392 is completely de-glycosylated by PNGase fol-
lowing protein degradation by the proteasome, allowing only the presentation of D-GP392.
Another possibility is that due to the significantly reduced binding affinity of GlcNAc-GP392
to H-2Db, with the glycan moiety pointing either in or out of the peptide-binding cleft, the
amounts of GlcNAc-GP392 presented on the cell surface are too low for efficient detection. It
is essential to note that in vivo peptide stimulation using N-glycosylated and de-N-glycosylated
versions of GP392 failed to generate CTL responses in C57/Bl6 mice [24].
In contrast to GP392, the GP92 epitope is not modified at position 5, but instead at position
4 (Fig 4A), causing peptide binding to be largely unaffected by glycosylation or de-glycosyla-
tion (Fig 4B and 4C). Indeed all forms of GP92 epitopes efficiently bind to H-2Db [24]. Instead,
glycosylation and any following modification would result in the formation T-cell neo-epi-
topes [23]. Formation of glycosylation/de-glycosylation derived neo-epitopes has been
reported in a large ensemble of diseases including ovarian carcinoma, melanoma, leukemia as
well as autoimmune diseases such as rheumatoid arthritis [12,13,15,60].
The epitope GlcNAc-GP92 is immunogenic with high affinity to H-2Db, but has not been
eluted from LCMV-infected cells, and CTLs stimulated with GlcNAc-GP92 epitope did not
kill LCMV-infected cells. [23]. In contrast, both wild-type GP92 and the de-glycosylated PTM
version D-GP92 are naturally presented on the cell surface. So why is GlcNAc-GP92 not pres-
ent? At the present time, we can only delve into this question through speculation. Glycosyla-
tion is known to affect the efficiency of proteases [20], which could be one reason to why only
the wild-type and the de-glycosylated peptide versions are detected. Assuming that the glyco-
sylated version is the functional state of this protein, the H-2Db-restricted peptide GP92 could
be a result of a misfolded and degraded protein, insusceptible to glycosylation at this position,
according to the Defect Ribosomal Product hypothesis [61].
Additional studies on the functional, structural and immunological relevance of the post-
translationally modified peptidome are necessary in order to expand our knowledge on the
pathways leading to the presentation of such peptides. Novel techniques using e.g. advanced
mass-spectrometry with high sensitivity [16,60,62,63] would allow the identification of dis-
ease-associated PTM neo-epitopes, and allow us to readdress previously published work in
order to assess whether glycosylated versions of GP92 are actually presented or not on the sur-
face of infected cells. Here we report the structural bases underlying how glycosylation of
GP92 can clearly result in the formation of immunogenic neo-epitopes that may select for dif-
ferent T cell populations. In contrast, glycosylation of GP392 inhibits the presentation of vari-
ants of this epitope, possibly resulting in immune evasion. In conclusion, our results provide
structural insights for how PTM neo-epitopes can be immunogenic while others are not. The
identification and exact understanding of the structural localization of such modifications,
especially when it comes to interaction with MHC-I molecules, is essential for the design of
efficient peptide vaccines against viral infections and cancer.
Supporting information
S1 Fig. Crystal structure of the prefusion surface glycoprotein of LCMV expressed in insect
cells reveals that GP is heavily glycosylated. Eight asparagine residues, N85, N95, N114,
N124, N171, N232, N371 and N396 glycosylated. Importantly bothpeptide GP92 and GP392,
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colored in green and blue, respectively, are glycosylated.
(TIF)
S2 Fig. Extensive network of hydrogen bonds between peptide and H-2Db.
(TIF)
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